A groundbreaking universal vaccine is in progress that could provide immunity against entire groups of viruses, aiming to prevent potential pandemics. British scientists are utilizing artificial intelligence (AI) to create this innovative vaccine, which is designed to offer protection against future virus mutations. This development comes as current vaccines lose effectiveness over time due to virus evolution, requiring constant updates.
Researchers from Cambridge and Southampton universities have successfully formulated a “game changer” vaccine that eliminates the possibility of viruses mutating to evade immunity. By analyzing global data on past virus mutations, the AI identified a crucial “super antigen” on the viral molecule essential for the survival of similar viruses.
Professor Saul Faust, the lead investigator from Southampton University, emphasized the continuous evolution of viruses like flu, coronaviruses, and the ebola group, highlighting the shortcomings of the reactive vaccine approach. The newly proposed universal vaccines are designed to simultaneously protect against multiple variants and potential emerging viruses, potentially saving millions of lives and averting future lockdowns.
The Covid-19 pandemic underscores the importance of adapting to rapidly evolving viruses, with existing vaccines failing to provide adequate protection. Professor Jonathan Heeney from Cambridge stressed the need to shift towards a new paradigm of vaccine development based on identifying essential elements shared among virus families, which are resistant to easy mutation.
The universal Sarbeco coronavirus vaccine, developed in collaboration with biotechnology company DIOSynVax, has shown promising results in initial trials on 49 healthy volunteers. Administered as a DNA vaccine using a needle-free method, the vaccine triggered an immune response not only against SARS-CoV-2 and SARS but also related bat viruses with zoonotic potential.
Further studies are planned to recruit over 200 volunteers for the phase II trial to test the vaccine’s efficacy against a broader range of coronaviruses. If successful, this technology has the potential to revolutionize viral protection, providing defense against a multitude of virus variants, including potential future threats like ebola.
Professor Marian Knight, scientific director for the National Institute for Health and Care Research (NIHR) Infrastructure, hailed the AI-designed super-antigen trial as a significant advancement in achieving broad and long-lasting viral protection. The study was sponsored by the University Hospital Southampton NHS Foundation Trust.